

Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only Doc. No.: 5109-24v04 Quantimal Malaria CELISA SDS

Issue Date: 6/12/2021 Authorised By: DDH

Page 1 of 7

Section 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name: Quantimal Malaria pLDH Antigen CELISA Product Code: KM7

Components: Microwell Plates Conjugate Diluent Substrate

Positive Control Washing Buffer Substrate Buffer
Negative Control Enzyme Conjugate Stopping Solution

1.2. Relevant identified uses of the substance or mixture and uses advised against

Enzyme-linked Immunosorbent Assay (ELISA) for the detection of antigen *Plasmodium* lactate dehydrogenase (pLDH) biomolecule, present in all species of malaria.

1.3. Details of the supplier of the safety data sheet

Company Details Contact Details

Cellabs Pty Ltd
7/27 Dale Street
Brookvale 2100
NSW, Australia
Telephone: +61 2 9905 0133
Fax: +61 2 9905 6426
email: admin@cellabs.com.au

1.4. Emergency telephone number

Emergency telephone: + 61 2 9905 0133 (office hours only)

Section 2: Hazards identification

2.1. Classification of the substance or mixture

Classification under 1272/2008 EC Regulation

Stopping Solution: Skin irrit. 2 H319

Eye irrit. 2 H315

All other components listed in Section 1.1 are not classified in CLP.

FOR TRANSPORT USING AIR (COURIERS): PLEASE NOTE THAT THE CONCENTRATION OF STOPPING SOLUTION IS VERY LOW AT 6.5% (less than the concentration limits of 10%) AND PACKAGED IN ACCEPTABLE QUANTITIES (30ML) THERFORE THIS KIT IS CLASSIFIED AS NON-HAZARDOUS LABORATORY DIAGNOSTIC KIT- SEE TRANSPORT CLASSIFICATION IN SECTION 14.

2.2. Label elements

Label elements: GHS



Hazard Pictograms

GHS05 GHS07

Signal Word : Danger



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only Doc. No.: 5109-24v04

Quantimal Malaria CELISA SDS

Issue Date: 6/12/2021 Authorised By: DDH

Page 2 of 7

Hazard Statements: H315 May cause skin irritation

H335 May cause respiratory irritationH290 May be corrosive to metals

Precautionary Statements: P201 Obtain special instructions before use

P234 Keep only in original container

P260-P261 Do not breath and avoid breathing mist/vapours/spray

P262 Do not get in eyes, on skin or on clothing

P280 Wear protective gloves/clothing/eye or face protection
P302 + 350 IF ON SKIN: Gently wash with plenty of soap and water

P304 + P340 + P341 IF INHALED: remove victim to fresh air and keep at

rest in a position comfortable for breathing.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several

minutes. Remove contact lenses if preset and continue rinsing

P306 + P360 IF ON CLOTHING: Rinse immediately contaminated clothing

and skin with plenty of water before removing clothes.

P308 + P313 IF exposed or concerned: Get medical advice/attention

P401 Store at 2-8oC

P501 Dispose of contents/container as per laboratory methods for acids.

2.3. Other hazards

PBT: This product is not identified as a PBT/vPvB substance.

Section 3: Composition/information on ingredients

3.1. Substances

Not Applicable

3.2. Mixtures

Stopping Solution

| Name | Product Identifier | | % | Classification GHS |
|-------------------------|--------------------|-----------------|-------|--------------------|
| Deionised water | CASNo. 7732-18-5 | ECNo. 231-595-7 | >90% | Not classified |
| Hydrochloric Acid (HCI) | CASNo. 7647-01-0 | | < 10% | Skin Irrit. 2 H315 |
| | | | | Eye irrit 2 H319 |

Contains: Contains no hazardous substances in reportable quantities under the CLP.

Refer to Section 16 for full description of H statements.

Section 4: First aid measures

4.1. Description of first aid measures

Skin contact: Wash immediately with plenty of soap and water.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present and

easy to do so. Continue rinsing. If eye irritation persists, seek medical advice/attention.

Ingestion: Do not induce vomiting. Wash mouth with water and give plenty of water to drink



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only
Doc. No.: 5109-24v04
Quantimal Malaria CELISA SDS
Issue Date: 6/12/2021
Authorised By: DDH

Page 3 of 7

immediately. Obtain medical attention if necessary and show label on container.

Inhalation: Irritation is unlikely to occur but in the event of discomfort, provide plenty of fresh air and if necessary seek medical assistance.

4.2. Most important symptoms and effects, both acute and delayed

Skin contact: There may be mild irritation at the site of contact.

Eye contact: There may be irritation and redness. **Ingestion:** There may be irritation of the throat.

Inhalation: No symptoms.

4.3. Indication of any immediate medical attention and special treatment needed

Immediate / special treatment: Not applicable.

Section 5: Fire-fighting measures

5.1. Extinguishing media

Extinguishing media: Suitable extinguishing media for the surrounding fire should be used. Use water spray

to cool containers.

5.2. Special hazards arising from the substance or mixture

Exposure hazards: No known specific hazards

5.3. Advice for fire-fighters

Advice for fire-fighters: Do not enter fire without proper protective equipment, including respiratory protection.

Section 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions: Refer to section 8 of SDS for personal protection details.

Turn leaking containers leak-side up to prevent the escape of liquid.

6.2. Environmental precautions

Environmental precautions: Do not discharge into drains or rivers.

6.3. Methods and material for containment and cleaning up

Clean-up procedures: For small spills, clean up with paper/cloth, or mop up, and dispose of safely.

Clean area of spillage down with plenty of water.

6.4. Reference to other sections

Reference to other sections: Refer to section 8 of SDS.

Section 7: Handling and storage

7.1. Precautions for safe handling

Handling requirements: No special requirements.

7.2. Conditions for safe storage, including any incompatibilities



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only
Doc. No.: 5109-24v04
Quantimal Malaria CELISA SDS

Issue Date: 6/12/2021 Authorised By: DDH

Page 4 of 7

Storage conditions: Store in a cool, well ventilated area.

Store in original container between 2°C and 8°C. Keep container tightly closed.

Suitable packaging: Must only be kept in original packaging.

7.3. Specific end use(s)

Specific end use(s): No data available.

Section 8: Exposure controls/personal protection

8.1. Control parameters

Workplace exposure limits: No data available.

DNEL/PNEC Values

DNEL / PNEC No data available.

8.2. Exposure controls

Engineering measures: Ensure all engineering measures mentioned in section 7 of SDS are in place.

Respiratory protection: Respiratory protection not required.

Hand protection: Protective gloves.

Eye protection: Use protective laboratory googles or hood with barrier.

Skin protection: Personal protective clothing or lab coat.

Section 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

State: Liquid

Colour: Colourless

Odour: Odourless

Solubility in water: Soluble

Viscosity: Non-viscous

Boiling point/range°C: No data available Melting point/range°C: No data available.

Flash point°C: No data available Autoflammability°C: No data available.

Vapour pressure: No data available. Relative density: No

pH: 0

9.2 Other information

Other information: No data available.

Section 10: Stability and reactivity

10.1. Reactivity

Reactivity: Stable under recommended transport or storage conditions.



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only
Doc. No.: 5109-24v04
Quantimal Malaria CELISA SDS
Issue Date: 6/12/2021
Authorised By: DDH

Page **5** of **7**

10.2. Chemical stability

Chemical stability: Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous reactions: Hazardous reactions will not occur under normal transport or storage conditions.

10.4. Conditions to avoid

Conditions to avoid: No known specific conditions to avoid

10.5. Incompatible materials

Materials to avoid: None known.

10.6. Hazardous decomposition products

Section 11: Toxicological information

11.1. Information on toxicological effects

| | Stopping Solution (<10% Conc. HCI) | | | |
|---------------|---|--|--|--|
| Specific | Eye Irrit. 2; H319: 10% ≤ C < 25% | | | |
| Concentration | Skin Irrit. 2; H315: 10% ≤ C < 25% | | | |
| limits | Skin Corr. 1B; H314: C ≥ 25% | | | |
| | STOT SE 3; H335: C ≥ 10% | | | |
| | Acute inhalation toxicity for >25% = LC50 Rat: 4.74 mg/L, 1 h (RTECS) | | | |

Section 12: Ecological information

12.1. Toxicity

Ecotoxicity values: No information available.

12.2. Persistence and degradability

Persistence and degradability: Not established

12.3. Bioaccumulative potential

Bioaccumulative potential: Partition coefficient: n-octano/water. Not applicable

12.4. Mobility in soil

Mobility: No information available

12.5. Results of PBT and vPvB assessment

PBT identification:

Stopping Solution: This product does not meet the criteria for PBT/vPvB according to Regulation EC No. 1907/2006, Annex XIII, or a PBT/vPvB assessment was not conducted.

12.6. Other adverse effects

Other adverse effects:



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only
Doc. No.: 5109-24v04
Quantimal Malaria CELISA SDS

Issue Date: 6/12/2021 Authorised By: DDH

Page 6 of 7

Stopping Solution (Hydrochloric Acid <10%): Forms corrosive mixtures with water even if diluted. Harmful effect due to pH shift. Discharge into the environment must be avoided.

Section 13: Disposal considerations

13.1. Waste treatment methods

Disposal operations:

Stopping Solution: Dispose of in accordance with current legislation and local authority regulations and in

accordance with Directive on waste 2008/98/EC. Leave in original container. No

mixing with other waste. Handle uncleaned product like the product itself.

NB: The user's attention is drawn to the possible existence of regional or national regulations regarding disposal.

Section 14: Transport information

IMPORTANT FOR COURIERS/TRANSPORT

Land Transport (ADR) Not subject to regulation as package sizes below limited quantities described in ADR

Sea transport (IMDG) Non examined Regulation

Air Transport (IATA) Exempted from the marking, labeling and documentation requirements of these

Regulations when shipped below limited quantities described.

14.1. UN number

UN number: N/A

14.2. UN proper shipping name

Shipping name: This product is not covered by international regulation on the transport of dangerous

goods (IMDG, IATA, ADR/RID).

Non-hazardous for rail or road, sea and air transport

14.3. Transport hazard class(es)

Not Applicable

14.4. Packing group

Not Applicable

14.5. Environmental hazards

No Information available

14.6. Special precautions for user

Special precautions: No special precautions.

Section 15: Regulatory information

15.1. Local Regulation

Specific regulations: No additional regulation applicable



Quantimal® Malaria pLDH Antigen CELISA

Section 5 Office Use Only Doc. No.: 5109-24v04 Quantimal Malaria CELISA SDS

Issue Date: 6/12/2021 Authorised By: DDH

Page **7** of **7**

15.2. International Regulation

Classification according to Regulation (EC) No. 1272/2008 (CLP)

Classification according to Directive 67/548/EEC or 1999/45/EC Not Classified

Section 16: Other information

| | mation |
|--|--------|
| | |
| | |

Full text of H Phrases: see Section 2.2

| H315 | Causes serious skin irritation | |
|------|--------------------------------|--|
| H319 | Causes serious eye irritation | |
| | | |

Legal disclaimer: The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. This company shall not be held liable for any damage resulting from handling or from contact with the above product.